Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
Identifieur interne : 004D78 ( Main/Exploration ); précédent : 004D77; suivant : 004D79Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
Auteurs : RBID : pubmed:8410279English descriptors
- KwdEn :
- Adenocarcinoma (immunology), Adenocarcinoma (radionuclide imaging), Aged, Aged, 80 and over, Antibodies, Bispecific (immunology), Antibodies, Monoclonal (immunology), Colorectal Neoplasms (immunology), Colorectal Neoplasms (radionuclide imaging), Female, Haptens, Humans, Immunoglobulin Fab Fragments (immunology), Indium Radioisotopes (diagnostic use), Indium Radioisotopes (immunology), Indium Radioisotopes (pharmacokinetics), Male, Middle Aged, Pentetic Acid (diagnostic use), Pentetic Acid (pharmacokinetics), Sensitivity and Specificity, Tissue Distribution.
- MESH :
- chemical , diagnostic use : Indium Radioisotopes, Pentetic Acid.
- chemical , immunology : Antibodies, Bispecific, Antibodies, Monoclonal, Immunoglobulin Fab Fragments, Indium Radioisotopes.
- immunology : Adenocarcinoma, Colorectal Neoplasms.
- chemical , pharmacokinetics : Indium Radioisotopes, Pentetic Acid.
- radionuclide imaging : Adenocarcinoma, Colorectal Neoplasms.
- Aged, Aged, 80 and over, Female, Haptens, Humans, Male, Middle Aged, Sensitivity and Specificity, Tissue Distribution.
Abstract
Eleven patients with primary colorectal carcinoma tumors (4 +/- 2 cm) were given intravenous injections of 1-10 mg of an anti-CEA, anti-In-DTPA bispecific Fab'-Fab monoclonal antibody, and 2-8 days later, were injected with 1.2-4.2 nmol of an 111In-labeled DTPA dimer (6 mCi). The bispecific antibody exhibited good stability and F(ab)'2-like pharmacokinetics. After injection, the 111In-DTPA dimer distributed in a large volume (88 ml/kg-180 ml/kg) and cleared through the kidneys (mean residence time in the whole body: 9 hr-16 hr). Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg). In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8). As a result, low background images allowed detection of 12 of 13 lesions, 4 hr and 24 hr after hapten injection. However, 7 of 11 patients developed HAMA.
PubMed: 8410279
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.</title><author><name sortKey="Le Doussal, J M" uniqKey="Le Doussal J">J M Le Doussal</name><affiliation wicri:level="1"><nlm:affiliation>Immunotech SA, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Immunotech SA, Marseille</wicri:regionArea><placeName><region type="région">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Chetanneau, A" uniqKey="Chetanneau A">A Chetanneau</name></author><author><name sortKey="Gruaz Guyon, A" uniqKey="Gruaz Guyon A">A Gruaz-Guyon</name></author><author><name sortKey="Martin, M" uniqKey="Martin M">M Martin</name></author><author><name sortKey="Gautherot, E" uniqKey="Gautherot E">E Gautherot</name></author><author><name sortKey="Lehur, P A" uniqKey="Lehur P">P A Lehur</name></author><author><name sortKey="Chatal, J F" uniqKey="Chatal J">J F Chatal</name></author><author><name sortKey="Delaage, M" uniqKey="Delaage M">M Delaage</name></author><author><name sortKey="Barbet, J" uniqKey="Barbet J">J Barbet</name></author></titleStmt><publicationStmt><date when="1993">1993</date><idno type="RBID">pubmed:8410279</idno><idno type="pmid">8410279</idno><idno type="wicri:Area/Main/Corpus">004E68</idno><idno type="wicri:Area/Main/Curation">004E68</idno><idno type="wicri:Area/Main/Exploration">004D78</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (immunology)</term><term>Adenocarcinoma (radionuclide imaging)</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Bispecific (immunology)</term><term>Antibodies, Monoclonal (immunology)</term><term>Colorectal Neoplasms (immunology)</term><term>Colorectal Neoplasms (radionuclide imaging)</term><term>Female</term><term>Haptens</term><term>Humans</term><term>Immunoglobulin Fab Fragments (immunology)</term><term>Indium Radioisotopes (diagnostic use)</term><term>Indium Radioisotopes (immunology)</term><term>Indium Radioisotopes (pharmacokinetics)</term><term>Male</term><term>Middle Aged</term><term>Pentetic Acid (diagnostic use)</term><term>Pentetic Acid (pharmacokinetics)</term><term>Sensitivity and Specificity</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Bispecific</term><term>Antibodies, Monoclonal</term><term>Immunoglobulin Fab Fragments</term><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adenocarcinoma</term><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Indium Radioisotopes</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Adenocarcinoma</term><term>Colorectal Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Haptens</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Sensitivity and Specificity</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Eleven patients with primary colorectal carcinoma tumors (4 +/- 2 cm) were given intravenous injections of 1-10 mg of an anti-CEA, anti-In-DTPA bispecific Fab'-Fab monoclonal antibody, and 2-8 days later, were injected with 1.2-4.2 nmol of an 111In-labeled DTPA dimer (6 mCi). The bispecific antibody exhibited good stability and F(ab)'2-like pharmacokinetics. After injection, the 111In-DTPA dimer distributed in a large volume (88 ml/kg-180 ml/kg) and cleared through the kidneys (mean residence time in the whole body: 9 hr-16 hr). Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg). In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8). As a result, low background images allowed detection of 12 of 13 lesions, 4 hr and 24 hr after hapten injection. However, 7 of 11 patients developed HAMA.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8410279</PMID><DateCreated><Year>1993</Year><Month>11</Month><Day>09</Day></DateCreated><DateCompleted><Year>1993</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>10</Issue><PubDate><Year>1993</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.</ArticleTitle><Pagination><MedlinePgn>1662-71</MedlinePgn></Pagination><Abstract><AbstractText>Eleven patients with primary colorectal carcinoma tumors (4 +/- 2 cm) were given intravenous injections of 1-10 mg of an anti-CEA, anti-In-DTPA bispecific Fab'-Fab monoclonal antibody, and 2-8 days later, were injected with 1.2-4.2 nmol of an 111In-labeled DTPA dimer (6 mCi). The bispecific antibody exhibited good stability and F(ab)'2-like pharmacokinetics. After injection, the 111In-DTPA dimer distributed in a large volume (88 ml/kg-180 ml/kg) and cleared through the kidneys (mean residence time in the whole body: 9 hr-16 hr). Uptake of 111In by the tumor using this two-step technique (1.8%-17.5% injected dose ID/kg, measured from surgical samples 48 hr after hapten injection) was not found significantly lower than that achieved with our reference 111In-labeled anti-CEA F(ab)'2 1 to 4 days after injection in six patients with similar clinical status (5.5%-30.2% ID/kg). In addition, tumor-to-blood and tumor-to-liver uptake ratios were significantly improved (blood 7.8 versus 4.2, liver 2.8 versus 0.8). As a result, low background images allowed detection of 12 of 13 lesions, 4 hr and 24 hr after hapten injection. However, 7 of 11 patients developed HAMA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Doussal</LastName><ForeName>J M</ForeName><Initials>JM</Initials><Affiliation>Immunotech SA, Marseille, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Chetanneau</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gruaz-Guyon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gautherot</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lehur</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Delaage</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Haptens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Immunoglobulin Fab Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Haptens</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8410279</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8410279
|texte= Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8410279" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |